Patent Review of Novel Biologics Targeting Opioid Use Disorder (2018–2024)
ACS Chemical Neuroscience · 2024
DOI: 10.1021/acschemneuro.4c00691 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Chemical Neuroscience, 2024. Verfasst von Samuel Obeng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas 79106, United…. Hauptthemen laut MEDLINE: Biological Products, Opioid-Related Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: NIDA NIH HHS, Ohio Northern University, National Institute of Health - NIDA.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Drug overdose deaths in 2023 in the United States exceeded 107,000, with 80,000 of these deaths attributed to opioids alone. The emergence of synthetic opioids such as fentanyl and its analogues have worsened the opioid overdose epidemic. A novel approach to treat opioid overdose and opioid use disorder (OUD) has been the introduction of biologics, which include monoclonal antibodies that bind to circulating opioids, preventing them from reaching the central nervous system, or peptides that have antinociceptive effects but lack the abuse liability of synthetic opioids. A challenge in the treatment of opioid overdose has been renarcotization, where an overdose patient revived with naloxone can re-enter an overdose state from residual opioid in the body. Biologics such as vaccines and monoclonal antibodies are excellent strategies that have been demonstrated to prevent renarcotization. In this review, we retrieved and discussed patents filed in the past six (6) years that focus on novel biologics reported as treatments for opioid overdose and OUD. We also provide a perspective on the use of biologics as therapeutics for OUD and opioid overdose.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas 79106, United States.
- Department of Pharmaceutical and Biomedical Sciences, Rudolph H. Raabe College of Pharmacy, Ohio Northern University, Ada, Ohio 45810, United States.
ORCID-Profile: Samuel Obeng, Edward Ofori
Förderung
- NIDA NIH HHS
- Ohio Northern University
- National Institute of Health - NIDA
Zitieren
APA
Obeng, S., McMahon, L. R., & Ofori, E. (2024). Patent Review of Novel Biologics Targeting Opioid Use Disorder (2018–2024). ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.4c00691
Vancouver
Obeng S, McMahon LR, Ofori E. Patent Review of Novel Biologics Targeting Opioid Use Disorder (2018–2024). ACS Chemical Neuroscience. 2024. doi:10.1021/acschemneuro.4c00691
BibTeX
@article{Obeng2024,
author = {Obeng, Samuel and McMahon, Lance R and Ofori, Edward},
title = {Patent Review of Novel Biologics Targeting Opioid Use Disorder (2018–2024)},
journal = {ACS Chemical Neuroscience},
year = {2024},
doi = {10.1021/acschemneuro.4c00691}
}
EUVIMED